Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2019

View Archived Issues

PARP degradation joins trapping, inhibition

Tau spreads quickly but kills slowly

HLX-11 receives IND application acceptance notification from NMPA

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

eFFECTOR Therapeutics initiates early clinical study of zotatifin in advanced solid tumors

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Initiation of phase Ib study of mavorixafor in severe congenital neutropenia

Regeneron provides updates on phase III development program of Libtayo in NSCLC

Daiichi Sankyo presents in vitro and in vivo data for DS-1039

NXP-031 leads to significant improvement of motor deficit in MPTP-induced mouse model of PD

Investigators design mouse model of dwarfism with PCSK1 mutation

EOLO-42016 shows promise in model of inherited ALS

Enzyme-replacement gene therapy encoding glucocerebrosidase attenuates PD phenotype

First phase I data presented for influenza vaccine OVX-836

Small molecules clear mutant Huntingtin protein

Tempest Therapeutics patents prostanoid EP2 and EP4 receptor antagonists

Incyte patent describes MAP4K1 inhibitors

TNBG-5602 induces lipid accumulation and antiproliferation in liver cancer cells through PPARgamma

Ark Biosciences reports topline proof-of-concept data for ziresovir in RSV

HitGen identifies new NTRK1 inhibitors

ATM and DNA-PK kinase inhibitors revealed in XRad Therapeutics patent

Shenzhen Targetrx Biotechnology patent details new tyrosine kinase inhibitors

4D reports preliminary phase I/II data on MRx-0518 with pembrolizumab in advanced malignancies

Dystrogen reports cardioprotective effects of DEC cells in Duchenne muscular dystrophy

BerGenBio reports updated phase II data on bemcentinib in advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...